- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT02531464
Intervention to Improve Supportive Care for Family Caregivers of Patients With Lung Cancer
Effectiveness of a Multi-faceted Intervention to Improve Supportive Care for Family Caregivers of Patients With Lung Cancer
Studieöversikt
Detaljerad beskrivning
Lung cancer may cause severe distress not only in patients but also in their family caregivers (FCs), with a direct impact on quality of life (QoL). Distress can be higher in FCs than in patients. Results from a recent study on continuity of cancer care conducted by the investigators support these findings, as a significantly larger proportion of FCs than patients reported high levels of anxiety and distress early after the diagnosis of lung cancer and this difference remained after 6 and 12 months. Several cancer centers have implemented systematic distress screening program during the care trajectory, but they target only patients without extending it to FCs. This study aims to implement and assess the effectiveness of a multi-faceted intervention to improve supportive care for FCs of patients with lung cancer.
Specific objectives:
To assess the effectiveness of the intervention on:
1.1 Caregivers' outcomes: distress (primary outcome), anxiety, depression, QoL, needs, burden, perception of health, preparedness in caregiving, perceived social support 1.2 Patients' outcomes: distress, anxiety, depression, QoL, pain and other symptom relief 1.3 Care process outcomes: FCs and patients' utilization of services
- To further document and describe:
2.1 In the experimental group: FCs perceived usefulness of the intervention and perceived effect on distress/QoL 2.2 In the oncology team: perceived usefulness of the intervention and perceived effect on their practice/organization of care Methods: An experimental design is used to test the intervention during 9 months in a pulmonary oncology clinic in Quebec City where a distress screening tool is implemented for cancer patients (but not for FCs). A total of 120 FCs of patients newly diagnosed with a non-surgical lung cancer, followed at the clinic have been randomly assigned to either the intervention (experimental group N=60) or to usual care (control group N=60). Considering a 20% withdrawal rate (due to death or severe deterioration of patients' condition), this sample size allows to detect a 33% difference in distress scores between the two groups, with an estimated baseline distress score (with the HADS) of 13.7±7 (range 0-42), a 5% alpha error and a power of 80%. The intervention comprises 3 components: 1) systematic distress screening and problems assessment of FCs at their relative's cancer diagnosis and then, every 2 months for a maximum of 9 months; 2) privileged contact with an oncology nurse away from the patient to further identify and address FCs' problems; 3) liaison by the oncology nurse with the family physician of FCs who have reported a high level of distress (score ≥ 4 on the distress thermometer, which indicates a need for intervention), or who have mentioned needing help. In both groups, outcomes related to FCs and to care processes are measured with validated tools at baseline and every 3 months, for a maximum of 9 months. Measures are taken at the same intervals with patients since their physical and mental health may influence FCs' distress. Individual interviews with 12 FCs are planned to assess the usefulness of the intervention and its effect on their QoL. Interviews with the pivot nurses in oncology will document their satisfaction regarding the intervention and its effect on their practice.
Relevance. This translational study aims to assess the effectiveness of an intervention that transfers into practice the main recommendations of governmental authorities and experts regarding integrated care to globally improve cancer supportive care. It has the potential to make a significant impact on the burden of disease for FCs and to improve their quality of care. If proven effective, the conditions of success of this intervention could be replicated in other settings and for other types of cancer.
Studietyp
Inskrivning (Faktisk)
Fas
- Inte tillämpbar
Kontakter och platser
Studieorter
-
-
-
Quebec, Kanada, G1V 4G5
- Institut universitaire de cardiologie et pneumologie de Québec (IUCPQ)
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Relative identified by patients diagnosed with inoperable lung cancer as their principal family caregiver; having a family physician
Exclusion Criteria:
- Cognitive disorder
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Stödjande vård
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: Experimental: supportive care
Family caregivers (FC) in the experimental arm (supportive care) will be exposed to a multi-faceted intervention to help them cope with their caregiving role, support them and respond to their needs; the intervention includes 3 components: 1) systematic distress screening and problems assessment of FCs at 2-month interval during the study period; 2) privileged contact with an oncology nurse away from the patient to further identify and address FCs' problems; 3) liaison by the oncology nurse with the family physician of FCs fwho will have reported high distress or needing help
|
Systematic distress screening and needs assessment of family caregivers of patients with lung cancer
|
Inget ingripande: Control: usual care
In the control arm (usual care), FCs will assist to their relative initial visit to the pivot nurse in oncology (PNO) .
The PNO screens patients for distress and assesses their needs.
She does a bio-psycho-social comprehensive evaluation and may provide help and information.
She responds to questions and refers to appropriate resources, staying available for patients and their FCs throughout the cancer care trajectory.
However, most PNO interventions target the patient, with no systematic distress screening and problems assessment for FCs, nor any service and resource specifically dedicated to them.
If FCs clearly express distress or particular needs, the PNO will address them or refer to appropriate resources, but, in usual care, only few FCs receive support services
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Change in the mean score of distress (Hospital Anxiety Depression Scale)
Tidsram: Baseline, after 3, 6 and 9 months
|
Measured by the Hospital Anxiety Depression Scale (HADS)
|
Baseline, after 3, 6 and 9 months
|
Change in the mean score of distress (Psychological distress scale used in the Quebec Health Survey)
Tidsram: Baseline, after, 3, 6 and 9 months
|
Measured by the Psychological distress scale used in the Quebec Health Survey
|
Baseline, after, 3, 6 and 9 months
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Change in the preparedness for Caregiving (8-item validated instrument)
Tidsram: Baseline, after 3, 6 and 9 months
|
8-item validated instrument measuring the perceived readiness for multiple domains of the caregiving role (providing physical care, emotional support, setting up in-home support services and dealing with the stress of caregiving); the scale varies from 0 to 4
|
Baseline, after 3, 6 and 9 months
|
Change in the caregiver's Burden Scale in End of Life Care
Tidsram: Baseline, after 3, 6 and 9 months
|
16-item instrument validated with FCs who assist cancer patients in palliative care; the scale varies from 1 to 4
|
Baseline, after 3, 6 and 9 months
|
Change in the family caregiver needs (Home Caregiver Need Survey)
Tidsram: Baseline, after 3, 6 and 9 months
|
Measured by the Home Caregiver Need Survey, a 25-item tool covering informational, practical, emotional and spiritual needs.
For each need, FCs indicate, on a 0 to 4 scale, its perceived importance and how well it is satisfied
|
Baseline, after 3, 6 and 9 months
|
Change in the family caregiver quality of life ( City-of-Hope Quality of Life Scale-Family Version)
Tidsram: Baseline, after 3, 6 and 9 months
|
Measured by the City-of-Hope Quality of Life Scale-Family Version, a 37-item validated instrument that assesses 4 quality of life domains (physical, psychological, social and spiritual), with questions using a 0-10 scale; only the 4 items related to the general assessment of each quality of life domain will be used
|
Baseline, after 3, 6 and 9 months
|
Variation in service and health care resource utilization
Tidsram: Baseline, after 3, 6 and 9 months
|
FCs will report the number of visits to their family physician and to any other health/psychosocial professional, meetings to support groups, use of community resources (volunteer services, respite, help for housework, etc.), use of sick leave, and prescription of sleeping pills, anxiolytic or antidepressant medications
|
Baseline, after 3, 6 and 9 months
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Utredare
- Huvudutredare: Michele Aubin, MD, PhD, Laval University
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- FRQS-30740
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Lungcancer
-
Chang Gung Memorial HospitalAvslutad
-
University of ZurichDeep Breath Intelligence (DBI)RekryteringLung-/luftvägssjukdomarSchweiz
-
424 General Military HospitalAvslutad
-
Celularity IncorporatedAvslutadSteg 2 Lung sarkoidos | Steg 3 Lung sarkoidosFörenta staterna
-
Centre Hospitalier Universitaire, AmiensAvslutadHemodialyskomplikation | Lung ultraljudFrankrike
-
Tuberculosis Research Centre, IndiaInternational Union Against Tuberculosis and Lung Diseases; Sarvodaya Charitable... och andra samarbetspartnersAktiv, inte rekryterandePre-extensivt läkemedelsresistent lung-TB | Behandling Intolerant multiresistent lung-TB | Icke-responsiv multiresistent lung-TBIndien
-
Papa Giovanni XXIII HospitalAvslutadLungtransplantation | Ex Vivo Lung PerfusionItalien
-
Pontificia Universidad Catolica de ChileRekryteringLung ultraljud | Öppen bukkirurgiChile
-
University of Colorado, DenverChildren's Hospital Colorado; Food and Drug Administration (FDA)AvslutadHypertoni;Lung;PrimärFörenta staterna
-
University Hospital, LilleAvslutad
Kliniska prövningar på Supportive care
-
Chunrui LiNanjing IASO Biotechnology Co., LtdRekryteringPlasmacellleukemi | Återfall/refraktärt multipelt myelomKina
-
Cellular Biomedicine Group Ltd.The First Affiliated Hospital with Nanjing Medical UniversityAvslutadEn fas 1-studie som utvärderar säkerhet och effekt av C-CAR011-behandling hos DLBCL-ämnen (C-CAR011)Refraktärt diffust stort B-cellslymfomKina
-
Nexcella Inc.Har inte rekryterat ännuLätt kedja (AL) amyloidosFörenta staterna
-
Second Affiliated Hospital, School of Medicine,...RekryteringÅterfall och refraktärt B-cellslymfomKina
-
Second Affiliated Hospital, School of Medicine,...RekryteringB-cells non-Hodgkin lymfomKina
-
University of California, San FranciscoIndragenLymfom | Leukemi | Plasmacelldyskrasi
-
Hebei Senlang Biotechnology Inc., Ltd.RekryteringLymfom | Multipelt myelom | Akut lymfoblastisk leukemiKina
-
Baylor College of MedicineThe Methodist Hospital Research Institute; Center for Cell and Gene Therapy...IndragenAkut lymfoblastisk leukemi | Non-hodgkin lymfomFörenta staterna
-
Nanjing IASO Biotechnology Co., Ltd.Ruijin HospitalRekryteringPlasmacellleukemi | Återfall/refraktärt multipelt myelomKina
-
Zhejiang UniversityYake Biotechnology Ltd.RekryteringMultipelt myelom | Ny diagnostumörKina